Eisai competitors

Zippia score 4.8

Eisai main competitors are AstraZeneca, Novartis, and Eli Lilly and Company.

Competitor Summary. See how Eisai compares to its main competitors:

Sanofi US has the most employees (110,000).
Employees at AstraZeneca earn more than most of the competitors, with an average yearly salary of $112,988.

Work at Eisai?

Share your experience

Eisai vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
Eisai	1995	4.8	Woodcliff Lake, NJ	2	$5.3B	1,864
Saol Therapeutics	2015	3.9	Roswell, GA	1	$2.2M	66
AstraZeneca	1999	4.6	Wilmington, DE	8	$25.9B	76,100
Eli Lilly and Company	1876	4.6	Indianapolis, IN	4	$45.0B	33,625
Endo Pharmaceuticals Inc	1997	4.7	Malvern, PA	3	$2.6B	385
Takeda Pharmaceuticals U.S.A., Inc.	1998	4.7	Deerfield, IL	14	$12.1B	30,481
Purdue Pharma L.P.	1892	4.9	Stamford, CT	2	$3.0B	5,000
Organon	-	4.5	-	-	$6.4B	158
Pharmacia	1901	4.3	Kalamazoo, MI	1	$130.0M	350
Upsher-Smith Laboratories	1919	4.7	Maple Grove, MN	4	$420.0M	550
Meda in the US	2001	4.7	Somerset, NJ	1	$80.0M	149
Forest Pharmaceuticals Inc	1954	4.2	Saint Louis, MO	1	$40.0M	50
Daiichi Sankyo	2005	4.8	Parsippany-Troy Hills, NJ	2	$9.0B	15,348
Allergan plc	1948	4.8	Irvine, CA	1	$7.2B	11,400
Axcan Pharma US Inc	1991	4.2	Birmingham, AL	1	$470.4M	525
Sanofi US	1973	4.3	Bridgewater, NJ	1	$980.0M	110,000
Depomed	1995	4.0	Newark, CA	2	$342.7M	494
Ferndale Laboratories	1897	4.0	Ferndale, MI	1	$66.5M	200
Novartis	1996	4.9	East Hanover, NJ	16	$51.7B	110,000
DUSA Pharmaceuticals	1991	4.4	Wilmington, MA	1	$45.3M	50
Arbor Pharmaceuticals	2006	4.6	Atlanta, GA	1	$175.0M	157

Rate how well Eisai differentiates itself from its competitors.

Eisai salaries vs competitors

Among Eisai competitors, employees at AstraZeneca earn the most with an average yearly salary of $112,988.

Compare Eisai salaries vs competitors

Company	Average salary	Hourly salary	Salary score
Eisai	$79,219	$38.09	-
Saol Therapeutics	$66,833	$32.13	-
AstraZeneca	$112,988	$54.32	-
Eli Lilly and Company	$100,905	$48.51	-
Endo Pharmaceuticals Inc	$78,978	$37.97	-
Takeda Pharmaceuticals U.S.A., Inc.	$85,837	$41.27	-

Compare Eisai job title salaries vs competitors

Company	Highest salary	Hourly salary
Eisai	$62,202	$29.90
Upsher-Smith Laboratories	$83,014	$39.91
Eli Lilly and Company	$82,140	$39.49
Novartis	$81,909	$39.38
AstraZeneca	$80,478	$38.69
Allergan plc	$78,280	$37.63
Axcan Pharma US Inc	$66,219	$31.84
DUSA Pharmaceuticals	$65,998	$31.73
Forest Pharmaceuticals Inc	$62,542	$30.07
Sanofi US	$62,448	$30.02
Takeda Pharmaceuticals U.S.A., Inc.	$62,221	$29.91
Purdue Pharma L.P.	$62,023	$29.82
Organon	$61,951	$29.78
Endo Pharmaceuticals Inc	$61,900	$29.76
Daiichi Sankyo	$61,768	$29.70
Pharmacia	$61,642	$29.64
Saol Therapeutics	$61,227	$29.44
Depomed	$61,135	$29.39
Arbor Pharmaceuticals	$60,877	$29.27
Ferndale Laboratories	$60,178	$28.93

Do you work at Eisai?

Is Eisai able to compete effectively with similar companies?

Eisai jobs

Eisai demographics vs competitors

Compare gender at Eisai vs competitors

Job title	Male	Female
Eisai	50%	50%
Daiichi Sankyo	51%	49%
AstraZeneca	52%	48%
Endo Pharmaceuticals Inc	52%	48%
Eli Lilly and Company	53%	47%
Arbor Pharmaceuticals	55%	45%

Male

Female

100%

75%

50%

25%

Arbor Pharmaceuticals

Eli Lilly and Company

Endo Pharmaceuticals Inc

AstraZeneca

Daiichi Sankyo

Eisai

25%

50%

75%

100%

Compare race at Eisai vs competitors

Company	White	Hispanic or Latino	Black or African American	Asian	Unknown	Diversity score
Eisai	58%	13%	12%	13%	4%	9.7
Eli Lilly and Company	59%	15%	9%	13%	4%	9.8
Arbor Pharmaceuticals	65%	10%	16%	5%	4%	7.8
AstraZeneca	60%	13%	11%	12%	4%	9.8
Daiichi Sankyo	60%	15%	11%	10%	4%	9.5
Endo Pharmaceuticals Inc	60%	13%	12%	11%	4%	9.8

Eisai and similar companies CEOs

CEOBio

Dan Peisert

Depomed

David A. Ricks

Eli Lilly and Company

I'm the chairman and CEO of Eli Lilly and Company, after holding management roles in the U.S., Canada and China, as well as running Lilly’s largest business unit. Before I joined Lilly in 1996, I worked as an account rep at IBM. I'm on the board of Adobe, and I'm chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). I also serve on the board of the Central Indiana Corporate Partnership. I'm a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Steering Committee, The Business Council, Business Roundtable and the National Council for Expanding American Innovation (NCEAI). I serve on the Riley Children’s Foundation’s board of governors. I am a digital media spokesperson for Lilly and discuss topics related to our company, our business and the health care environment. We operate in a highly regulated environment, and only designated employees can discuss our products or pipeline. If you need information about our products or have questions or concerns, please visit these resources: https://e.lilly/guidelines

John Fraher

Axcan Pharma US Inc

John Fraher is a Chief Executive Officer at Aptalis Pharma Inc, Chief Executive Officer at Eurand NV, and Board Member at Ellodi Pharmaceuticals and is based in United States. He has worked as Pres:Aptalis Pharma Technologies at Aptalis Pharma Inc, Production Manager at Fort Dodge Animal Health, and President at Aptalis Pharma Inc. John works or has worked as President:America at Eurand Pharmaceuticals Hldg. He attended University College Dublin between 1984 and 1989.

Pascal Soriot

AstraZeneca

Ken Keller

Daiichi Sankyo

Paul Campanelli

Endo Pharmaceuticals Inc

Vasant Narasimhan

Novartis

Vasant "Vas" Narasimhan is an American physician and the chief executive officer of Novartis (since 2018).

Mark Morse

Pharmacia

Craig Landau

Purdue Pharma L.P.

Craig Landau is a President/CEO at Purdue Biopharma LP and President/CEO at PURDUE PHARMA and is based in Stamford, Connecticut. He has worked as Major at United States Army, Associate Medical Director at Knoll Pharmaceutical Co, and Executive Medical Director at PURDUE PHARMA. Craig attended WINTHROP-UNIVERSITY HOSPITAL between 1991 and 1992, Icahn School of Medicine at Mount Sinai between 1987 and 1991, and Yale University-School of Medicine between 1992 and 1995.

Paul Hudson

Sanofi US